{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:25:38Z","timestamp":1790367938885,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.drugalcdep.2013.04.025","type":"journal-article","created":{"date-parts":[[2013,6,6]],"date-time":"2013-06-06T10:33:15Z","timestamp":1370514795000},"page":"15-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Emerging pharmacotherapies for alcohol dependence: A systematic review focusing on reduction in consumption"],"prefix":"10.1016","volume":"133","author":[{"given":"Henri-Jean","family":"Aubin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Daeppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/039463200301600304","article-title":"Metadoxine in the treatment of acute and chronic alcoholism: a review","volume":"16","author":"Addolorato","year":"2003","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0015","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0020","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0025","first-page":"47","article-title":"Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project","volume":"420","author":"Alonso","year":"2004","journal-title":"Acta Psychiat. Scand."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0740-5472(01)00210-0","article-title":"Reduced-risk drinking as a treatment goal: what clinicians need to know","volume":"22","author":"Ambrogne","year":"2002","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","article-title":"Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician","volume":"40","author":"Ameisen","year":"2005","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0040","unstructured":"American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Text Revision American Psychiatric Association, Washington, DC."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0045","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0050","unstructured":"American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision American Psychiatric Association, Washington D.C."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0055","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","article-title":"A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence","volume":"28","author":"Anton","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0065","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0b013e3181aba6a4","article-title":"Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms","volume":"29","author":"Anton","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0075","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1530-0277.2008.00735.x","article-title":"Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers","volume":"32","author":"Arias","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0080","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e3181db38bb","article-title":"Placebo-controlled trial of zonisamide for the treatment of alcohol dependence","volume":"30","author":"Arias","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0085","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/j.1360-0443.2008.02355.x","article-title":"Comparing topiramate with naltrexone in the treatment of alcohol dependence","volume":"103","author":"Baltieri","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0090","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1017\/S1461145706007164","article-title":"The efficacy of the dopamine D2\/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients","volume":"10","author":"Bender","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.drugalcdep.2003.11.012","article-title":"Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology","volume":"74","author":"Chick","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3949\/ccjm.73.7.641","article-title":"Drug adjuncts for treating alcohol dependence","volume":"73","author":"Collins","year":"2006","journal-title":"Cleveland Clinic J. Med."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0105","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1530-0277.2006.00082.x","article-title":"A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients","volume":"30","author":"Croissant","year":"2006","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0110","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsat.2007.05.012","article-title":"An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence","volume":"34","author":"De Sousa","year":"2008","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0115","unstructured":"Department of Health, 2004. Alcohol Needs Assessment Research Project (ANARP) (cited 2012 20 April); Available from: http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/documents\/digitalasset\/dh_4122239.pdf."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0120","first-page":"86","article-title":"Motivation for change and alcoholism treatment","volume":"23","author":"DiClemente","year":"1999","journal-title":"Alcohol Res. Health"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0125","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.ALC.0000130974.50563.04","article-title":"Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy","volume":"28","author":"Dundon","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0130","unstructured":"EMA, 2010. Guideline on the development of medicinal products for the treatment of alcohol dependence (cited 2012 June 18); Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/03\/WC500074898.pdf."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0135","unstructured":"EMA, 2013. European public assessment report (EPAR) for Selincro (cited 2013 March 15); Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002583\/human_med_001620.jsp&mid=WC0b01ac058001d124."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.drugalcdep.2008.06.006","article-title":"A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence","volume":"99","author":"Farren","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0145","first-page":"236","article-title":"Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12 month follow-up study","volume":"35","author":"Fernandez Miranda","year":"2007","journal-title":"Actas Esp. Psiquiatr."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0150","series-title":"Currents of Alcoholism","article-title":"Diagnosis of alcoholism: the Munich Alcoholism Test (MALT)","author":"Feuerlein","year":"1980"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0155","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1530-0277.2008.00680.x","article-title":"Using topiramate or naltrexone for the treatment of alcohol-dependent patients","volume":"32","author":"Florez","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000320471","article-title":"Topiramate for the treatment of alcohol dependence: comparison with naltrexone","volume":"17","author":"Florez","year":"2011","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0165","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.v68n1108","article-title":"Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Furieri","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0170","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.281.14.1318","article-title":"Pharmacological treatment of alcohol dependence: a review of the evidence","volume":"281","author":"Garbutt","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0175","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jsat.2006.09.008","article-title":"Reduction in heavy drinking as a treatment outcome in alcohol dependence","volume":"33","author":"Gastfriend","year":"2007","journal-title":"J Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0185","unstructured":"Gual, A., He, Y., Torup, L., van den Brink, W., Mann, K., 2012. ESENSE 2: a randomised, double-blind, placebo-controlled study of nalmefene, as-needed use in alcohol dependent patients. Presented at the 35th Annual Scientific Meeting of the Research Society on Alcoholism, June 23\u201327, San Francisco, California. Alcohol. Clin. Exp. Res. 36, 246A."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0190","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.ALC.0000125352.06688.F7","article-title":"A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder","volume":"28","author":"Guardia","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1747-597X-1-35","article-title":"A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence","volume":"1","author":"Guerrini","year":"2006","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0200","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0306-4603(96)00013-5","article-title":"Drinking goal selection in behavioral self-management treatment of chronic alcoholics","volume":"22","author":"Hodgins","year":"1997","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0205","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0210","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0215","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","article-title":"Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial","volume":"61","author":"Johnson","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0220","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0225","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","article-title":"Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial","volume":"168","author":"Johnson","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0230","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0235","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study","volume":"31","author":"Karhuvaara","year":"2007","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0240","first-page":"858","article-title":"The treatment gap in mental health care","volume":"82","author":"Kohn","year":"2004","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0245","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/01.ALC.0000075547.77464.76","article-title":"Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study","volume":"27","author":"Kranzler","year":"2003","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JCP.0b013e31820465fa","article-title":"A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype","volume":"31","author":"Kranzler","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0255","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1360-0443.2006.01576.x","article-title":"Topiramate reduces the harm of excessive drinking: implications for public health and primary care","volume":"101","author":"Ma","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0260","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00213-005-0243-9","article-title":"Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial","volume":"184","author":"Mann","year":"2006","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0265","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2012","journal-title":"Biol. Psych."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0270","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0306-4603(02)00294-0","article-title":"Harm reduction approaches to alcohol use: health promotion, prevention, and treatment","volume":"27","author":"Marlatt","year":"2002","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0275","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1530-0277.2002.tb02454.x","article-title":"Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial","volume":"26","author":"Marra","year":"2002","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0280","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1056\/NEJMsa022615","article-title":"The quality of health care delivered to adults in the United States","volume":"348","author":"McGlynn","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0285","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1360-0443.2006.01310.x","article-title":"Rates and predictors of relapse after natural and treated remission from alcohol use disorders","volume":"101","author":"Moos","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0290","first-page":"320","article-title":"Use of anti-craving agents in soldiers with alcohol dependence syndrome","volume":"64","author":"Narayana","year":"2008","journal-title":"MJAFI"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0295","unstructured":"National Institute on Alcohol Abuse and Alcoholism, 2006. Cognitive Behavioral Coping Skills Therapy Manual [cited 2013 13 March]."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0300","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1530-0277.2008.00682.x","article-title":"Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial","volume":"32","author":"O\u2019Malley","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0305","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1177\/0269881109103799","article-title":"An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects","volume":"24","author":"Paparrigopoulos","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0310","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/0093854808320169","article-title":"Offender coercion in treatment: a meta-analysis of effectiveness","volume":"35","author":"Parhar","year":"2008","journal-title":"Crim. Justice Behav."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0315","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00004714-200104000-00005","article-title":"Double-blind clinical trial of sertraline treatment for alcohol dependence","volume":"21","author":"Pettinati","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0320","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/10550490490459906","article-title":"Gender differences in response to sertraline pharmacotherapy in Type A alcohol dependence","volume":"13","author":"Pettinati","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0325","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0330","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/j.1530-0277.2008.00717.x","article-title":"Prediction of serotonergic treatment efficacy using age of onset and Type A\/B typologies of alcoholism","volume":"32","author":"Roache","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0335","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1360-0443.2011.03752.x","article-title":"Alcohol-dependence: the current French craze for baclofen","volume":"107","author":"Rolland","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0269881107078308","article-title":"Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes","volume":"22","author":"Rosner","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0345","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0350","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/JCP.0b013e3181bfdb79","article-title":"Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence","volume":"29","author":"Rubio","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0355","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/WNF.0b013e3181f0ed9a","article-title":"Effects of zonisamide in the treatment of alcohol dependence","volume":"33","author":"Rubio","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0360","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0365","unstructured":"SAMHSA, 2009. The NSDUH Report: Alcohol Treatment: Need, Utilization, and Barriers. Rockville, MD."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0370","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0278-5846(01)00214-7","article-title":"Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence","volume":"26","author":"Schmidt","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0375","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1176\/ajp.127.12.1653","article-title":"The Michigan alcoholism screening test: the quest for a new diagnostic instrument","volume":"127","author":"Selzer","year":"1971","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0380","series-title":"Measuring Alcohol Consumption: Psychosocial and Biological Methods","first-page":"41","article-title":"Timeline followback: A technique for assessing self-reported alcohol consumption","author":"Sobell","year":"1992"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0385","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.phrs.2008.03.001","article-title":"An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients","volume":"57","author":"Stella","year":"2008","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0390","doi-asserted-by":"crossref","unstructured":"van den Brink, W., Aubin, H.-J., Bladstrom, A., Torup, L., Mann, K., Gual, A., 2013a. ESENSE 1\u2014Randomised controlled 6-month study of as-needed nalmefene: subgroup analysis of alcohol dependent patients with high drinking risk level. Presented at the 21st European Congress of Psychiatry, April 6\u20139, Nice, France.","DOI":"10.1016\/S0924-9338(13)76212-6"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0395","doi-asserted-by":"crossref","unstructured":"van den Brink, W, Aubin, H.-J., Sorensen, P., Torup, L., Mann, K., Gual, A., 2013b. ESENSE 2\u2014Randomised controlled 6-month study of as-needed nalmefene: subgroup analysis of alcohol dependent patients with high drinking risk level. Presented at the 21st European Congress of Psychiatry, April 6\u20139, Nice, France.","DOI":"10.1016\/S0924-9338(13)76213-8"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0400","doi-asserted-by":"crossref","unstructured":"van den Brink, W., Sorensen, P., Mann, K., Gual, A., 2013c. Long-term efficacy of nalmefene as-needed in alcohol-dependent patients with high drinking risk levels: results of a subgroup analysis. Presented at the 21st European Congress of Psychiatry, April 6\u20139, Nice, France.","DOI":"10.1016\/S0924-9338(13)76211-4"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0405","unstructured":"van den Brink, W., Sorensen, P., Torup, L., Gual, A., 2012. Long-term efficacy, tolerability, and safety of nalmefene as-needed in alcohol-dependence: a randomised, double-blind, placebo-controlled study. Presented at the 35th Annual Scientific Meeting of the Research Society on Alcoholism, June 23\u201327, San Francisco, California. Alcohol. Clin. Exp. Res. 36, 247A."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0410","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0415","series-title":"Enhanced Medication and Treatment Adherence for Addiction Treatment","author":"Volpicelli","year":"2001"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0420","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/alcalc\/36.4.329","article-title":"Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study","volume":"36","author":"Wiesbeck","year":"2001","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0425","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00737-003-0010-z","article-title":"Gender-related differences in pharmacological relapse prevention with flupenthixol decanoate in detoxified alcoholics","volume":"6","author":"Wiesbeck","year":"2003","journal-title":"Arch. Womens Ment. Health"},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0430","unstructured":"World Health Organization, 1992. International Statistical Classification of Diseases and Related Health Problems. Geneva, Switzerland."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0435","unstructured":"World Health Organization, 2004. The Global Burden of Disease. 2004 update (cited 2012 July 26); Available from: http:\/\/www.who.int\/healthinfo\/global_burden_disease\/GBD_report_2004update_full.pdf."},{"key":"10.1016\/j.drugalcdep.2013.04.025_bib0440","unstructured":"World Health Organization, 2007. WHO Expert Committee on Problems Related to Alcohol Consumption (cited 2012 30 July); Available from: http:\/\/www.who.int\/substance_abuse\/expert_committee_alcohol_trs944.pdf."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871613001543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871613001543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T16:38:22Z","timestamp":1588955902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871613001543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0376871613001543"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.04.025","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging pharmacotherapies for alcohol dependence: A systematic review focusing on reduction in consumption","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}